Compare Divis Laboratories with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NEULAND LABS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NEULAND LABS DIVIS LABORATORIES/
NEULAND LABS
 
P/E (TTM) x 59.7 70.0 85.3% View Chart
P/BV x 13.8 2.5 551.1% View Chart
Dividend Yield % 0.4 0.1 306.9%  

Financials

 DIVIS LABORATORIES   NEULAND LABS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
NEULAND LABS
Mar-20
DIVIS LABORATORIES/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,639754 217.5%   
Low Rs1,115247 450.9%   
Sales per share (Unadj.) Rs186.3594.5 31.3%  
Earnings per share (Unadj.) Rs51.012.6 403.4%  
Cash flow per share (Unadj.) Rs57.337.0 154.9%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.4 290.7%  
Book value per share (Unadj.) Rs261.8553.4 47.3%  
Shares outstanding (eoy) m265.4712.83 2,069.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.40.8 878.0%   
Avg P/E ratio x27.039.6 68.2%  
P/CF ratio (eoy) x24.013.5 177.7%  
Price / Book Value ratio x5.30.9 581.7%  
Dividend payout %31.415.8 198.3%   
Avg Mkt Cap Rs m365,5926,421 5,693.9%   
No. of employees `00011.81.3 924.1%   
Total wages/salary Rs m5,4231,236 438.9%   
Avg. sales/employee Rs Th4,175.15,949.4 70.2%   
Avg. wages/employee Rs Th457.7963.8 47.5%   
Avg. net profit/employee Rs Th1,141.8126.4 903.2%   
INCOME DATA
Net Sales Rs m49,4637,627 648.5%  
Other income Rs m1,55639 4,005.9%   
Total revenues Rs m51,0197,666 665.5%   
Gross profit Rs m18,7181,019 1,837.2%  
Depreciation Rs m1,689313 540.0%   
Interest Rs m35216 16.2%   
Profit before tax Rs m18,551529 3,505.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023367 1,368.3%   
Profit after tax Rs m13,527162 8,346.1%  
Gross profit margin %37.813.4 283.3%  
Effective tax rate %27.169.4 39.0%   
Net profit margin %27.32.1 1,287.0%  
BALANCE SHEET DATA
Current assets Rs m46,5015,152 902.6%   
Current liabilities Rs m8,4683,576 236.8%   
Net working cap to sales %76.920.7 372.2%  
Current ratio x5.51.4 381.2%  
Inventory Days Days131105 124.5%  
Debtors Days Days8691 94.5%  
Net fixed assets Rs m25,7973,969 650.0%   
Share capital Rs m531129 411.6%   
"Free" reserves Rs m68,9626,971 989.3%   
Net worth Rs m69,4937,100 978.8%   
Long term debt Rs m0774 0.0%   
Total assets Rs m80,38312,310 653.0%  
Interest coverage x531.03.5 15,378.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 99.3%   
Return on assets %16.93.1 549.7%  
Return on equity %19.52.3 852.7%  
Return on capital %26.79.5 282.7%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2385,187 795.1%   
Fx outflow Rs m12,4051,593 778.8%   
Net fx Rs m28,8333,594 802.3%   
CASH FLOW
From Operations Rs m9,543573 1,664.3%  
From Investments Rs m-6,854-487 1,408.0%  
From Financial Activity Rs m-2,459-55 4,488.0%  
Net Cashflow Rs m23033 704.3%  

Share Holding

Indian Promoters % 52.0 36.3 143.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 63.7 18.5%  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 63.7 27.0%  
Shareholders   31,796 12,705 250.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades Lower, Top 6 Factors Behind the Stock Market Rally, L&T Finance Holdings Rights Issue, and Buzzing Stocks Today(Pre-Open)

Indian share markets rallied nearly 2% yesterday, boosted by realty and finance stocks. Benchmark indices registered sharp gains yesterday after a massive selloff in the past two days.

Related Views on News

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 19, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - JUBILANT LIFE SCIENCES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS